

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 (Currently amended). An injectable chemotherapeutic pharmaceutical composition consisting of a halogenated xanthene at a concentration of greater than about 0.001% to less than about 20% in aqueous solution, wherein said halogenated xanthene is disodium 4,5,6,7-Tetrabromoerythrosin, ~~wherein the functionalities at positions R¹ and R² each comprise an element selected from the group consisting of sodium, potassium and hydrogen;~~ and wherein said pharmaceutical composition is adapted for chemotherapeutic treatment of cancer ~~diseases of human tissue.~~

2-9 (Canceled).

10 (Currently amended). The pharmaceutical composition of Claim 1 wherein said pharmaceutical composition is for the treatment of cancer ~~indications selected from the group consisting of diseases of the skin and related organs, diseases of the mouth and digestive tract and related organs, diseases of the urinary and reproductive tracts and related organs, diseases of the respiratory tract and related organs, diseases of the circulatory system and related organs, diseases of the head and neck, diseases of and the endocrine and lymphoreticular systems and related organs, diseases of connective tissues, diseases of tissue surfaces exposed during surgery, and diseases caused by microbial, viral, fungal, and parasitic infection.~~

11-35 (Canceled).

36 (Currently amended). An injectable chemotherapeutic pharmaceutical composition consisting of a halogenated xanthene in aqueous solution, wherein said halogenated xanthene is disodium 4,5,6,7-Tetrabromoerythrosin, ~~wherein the functionalities at positions R^1 and R^2 each comprise an element selected from the group consisting of sodium, potassium and hydrogen,~~ said halogenated xanthene present in a concentration of greater than about 0.001% to less than about 20%, and wherein said pharmaceutical composition is adapted for chemotherapeutic treatment of cancer ~~diseases of human tissue.~~

37 (Currently amended). An injectable chemotherapeutic pharmaceutical composition consisting of a halogenated xanthene in aqueous solution, wherein said halogenated xanthene is disodium 4,5,6,7-Tetrabromoerythrosin, ~~wherein the functionalities at positions R^1 and R^2 each comprise an element selected from the group consisting of sodium, potassium and hydrogen,~~ said halogenated xanthene present in a concentration of about 10%, and wherein said pharmaceutical composition is adapted for chemotherapeutic treatment of cancer ~~diseases of human tissue.~~